Previously, hyperexpression of HER-2 in the tumor has been found to correlate with ESCC progression and is significantly more common in patients developing early local relapses or distant metastases following surgery, however, this correlation has not been found in EGFR (19), as shown in the current study. Here, ERBB2 is linked to neoplasm.